Effect of Dapagliflozin on Left Atrial Strain Parameters in Diabetic Patients with Paroxysmal Atrial Fibrillation
Nada, F., El Merry, M., Abdellah, A. (2025). Effect of Dapagliflozin on Left Atrial Strain Parameters in Diabetic Patients with Paroxysmal Atrial Fibrillation. EKB Journal Management System, 28(1), 16-27. doi: 10.21608/scumj.2025.416334
Fathy Nada; Mohammed El Merry; Ahmed Abdellah. "Effect of Dapagliflozin on Left Atrial Strain Parameters in Diabetic Patients with Paroxysmal Atrial Fibrillation". EKB Journal Management System, 28, 1, 2025, 16-27. doi: 10.21608/scumj.2025.416334
Nada, F., El Merry, M., Abdellah, A. (2025). 'Effect of Dapagliflozin on Left Atrial Strain Parameters in Diabetic Patients with Paroxysmal Atrial Fibrillation', EKB Journal Management System, 28(1), pp. 16-27. doi: 10.21608/scumj.2025.416334
Nada, F., El Merry, M., Abdellah, A. Effect of Dapagliflozin on Left Atrial Strain Parameters in Diabetic Patients with Paroxysmal Atrial Fibrillation. EKB Journal Management System, 2025; 28(1): 16-27. doi: 10.21608/scumj.2025.416334

Effect of Dapagliflozin on Left Atrial Strain Parameters in Diabetic Patients with Paroxysmal Atrial Fibrillation

Suez Canal University Medical Journal
Article 3, Volume 28, Issue 1, January 2025, Page 16-27  XML PDF (426.72 K)
Document Type: Original Article
DOI: 10.21608/scumj.2025.416334
View on SCiNiTO View on SCiNiTO
Authors
Fathy Nada email orcid ; Mohammed El Merryorcid ; Ahmed Abdellah
Cardiology department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background: Atrial fibrillation (AF) is a common arrythmia in diabetes mellitus (DM). Left atrial strain (LAS) and electromechanical delay (EMD) are important AF predictors. Aim: To investigate the effect of dapagliflozin added to the standard antidiabetic treatment on LAS and EMD in type 2 DM (T2DM) patients with paroxysmal AF. Subjects and Methods: Diabetic patients in sinus rhythm with history of paroxysmal AF diagnosed by Holter electrocardiogram (ECG) or hospitalization were assigned into 2 groups. Dapagliflozin group: dapagliflozin 10 mg added to the standard antidiabetic treatment. Control group: standard antidiabetic treatment without added Sodium-Glucose-Cotransporter inhibitors (SGLT2i). Both groups were on beta blockers to prevent AF recurrence. We assessed baseline characteristics, echocardiography, LAS, EMD, and paroxysmal AF prevalence in both groups. Results: Dapagliflozin group (113 patients) has a postive improvement in diastolic function (E/e’ reduced from 9.9±2.4 to 7.8±1.8, P< 0.01), LA reservoir strain (26.5±7.9% to 28.9±3.8%, P< 0.015), LA contraction strain (10.8±4.9% to 12.2±5.9%, P< 0.021), and interatrial EMD (29.75±7.53 to 21.72±4.51 milliseconds, P< 0.029) at 12-months follow-up. Likewise, paroxysmal AF has occurred in 7.1% of dapagliflozin group vs 13.8% in control group at 12-months follow-up, P value Conclusion: Dapagliflozin addition to the standard antidiabetic treatment was associated with reduction of LA strain and interatrial electromechanical delay in type 2 DM patients who have paroxysmal AF. Moreover, this was associated with reduction of paroxysmal AF recurrence as documented by Holter ECG or hospitalization.
Keywords
Dapagliflozin; Diabetes Mellitus; LA Strain; Paroxysmal AF; Interatrial EMD
Statistics
Article View: 95
PDF Download: 60